|Podcasts|January 19, 2011
Build A Drug's Value in Early
Advertisement
Build a Drug's Value in Early
Mark Clein, President of United BioSource (UBC), discusses the company’s recent acquisition of Total Healthcare Group, a London-based consultancy on payer research, strategic planning and global value dossiers for the biopharma industry. Clein also discusses the current focus on comparative effectiveness, evidence-based research and value in medicines and how that impacts the Phase I through III development environment.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Beyond Compliance: AJNA BioSciences' Joel Stanley on Bringing Botanical Medicine Through the FDA Pathway
2
Where AI Is Delivering Real Value in Clinical Trial Payments Right Now
3
ACT Brief: AI in Invoice Processing, Botanical Medicines and FDA Pathways, and Connected Trial Finance Systems
4
From Doing to Reviewing: How a Connected Ecosystem Streamlines Clinical Trial Finance
5